Monitoring donor-specific antibodies in lung transplant patients
Monitoring of Donor-specific Antibodies (DSA) After Combined Treatment with Immunoglobulin a and Immunoglobulin M-enriched Intravenous Human Immunoglobulins and Plasmapheresis and Rituximab in Lung Transplantation
Hannover Medical School · NCT03798860
This study is testing a treatment plan for lung transplant patients with donor-specific antibodies to see if it helps manage their condition better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 75 (estimated) |
| Sex | All |
| Sponsor | Hannover Medical School (other) |
| Drugs / interventions | Rituximab |
| Locations | 1 site (Hannover) |
| Trial ID | NCT03798860 on ClinicalTrials.gov |
What this trial studies
This observational study aims to monitor the treatment of donor-specific antibodies in lung transplant recipients. It will evaluate the effectiveness of a treatment protocol that includes Immunoglobulins, and potentially a combination of Immunoglobulins, Plasmapheresis, and Rituximab. Participants will be lung transplant patients who have detectable donor-specific antibodies, and blood samples will be collected for analysis. The study is designed to provide insights into the management of antibody-mediated rejection in lung transplantation.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who have undergone lung transplantation and have detectable donor-specific antibodies.
Not a fit: Patients who have not undergone lung transplantation or do not have detectable donor-specific antibodies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the management of donor-specific antibodies, potentially enhancing transplant outcomes for lung transplant recipients.
How similar studies have performed: While this approach is observational, similar studies have shown promise in managing donor-specific antibodies in other types of organ transplantation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * all patients after lung transplantation with detection of donor-specific antibodies Exclusion Criteria: * none
Where this trial is running
Hannover
- Hannover Medical School, Department of Cardiothoracic, Transplant and Vascular Surgery — Hannover, Germany (RECRUITING)
Study contacts
- Principal investigator: Fabio Ius, Dr. — Hannover Medical School
- Study coordinator: Fabio Ius, Dr.
- Email: Ius.Fabio@mh-hannover.de
- Phone: +49 511-532-2125
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Transplantation, Donor-specific Anti-human Leukocyte Antigen Antibodies